Physician profile
David B Beckstead
NPI 1801909122
$1,069.63
in general payments reported to CMS, 2019-2025
16 companies · $85.17 in 2025
The $85.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.91 · 2020: $158 · 2021: $319 · 2022: $267 · 2023: $37.01 · 2024: $107 · 2025: $85.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.71 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.43 | 2020-2025 | |
| Amgen INC. | $100.78 | 2019-2021 | |
| Pfizer INC. | $78.26 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $68.08 | 2019-2022 | |
| Lilly USA, LLC | $63.73 | 2020-2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $50.31 | 2020-2022 | |
| Clarus Therapeutics INC. | $47.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.09 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.97 | 2022 | |
| Electromed, INC. | $13.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.25 | 2020 | |
| Dompe US, INC. | $13.09 | 2024 | Oxervate |
| Genzyme Corporation | $12.38 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beckstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.